Four Decades of Progress: A Letter to Our Readers

This year marks the 40th anniversary of ONCOLOGY. Over the past 4 decades, the field of oncology has undergone a transformational change that few could have anticipated, one defined by scientific acceleration, therapeutic innovation, and a steadily expanding vision of what cancer care can and should be. It is a privilege to reflect on this progress with our readers, authors, reviewers, and editorial colleagues who have contributed to and shaped the journal as well as the field it serves.

When ONCOLOGY was launched, modern cancer care was entering a pivotal phase. Cytotoxic chemotherapy had begun to demonstrate meaningful benefit, radiation therapy and surgical techniques were advancing, and clinical trials were increasingly informing standards of care. Across its pages, the journal chronicled this evolution by publishing studies and expert analyses that helped refine combination chemotherapy, establish adjuvant and neoadjuvant strategies, and advance multimodality treatment approaches that improved outcomes for patients with both localized and advanced disease.

As cancer biology moved from descriptive pathology toward molecular understanding, ONCOLOGY served as a forum for work elucidating hormone signaling, oncogenic pathways, and mechanisms of resistance. The journal published research and clinical insights that foreshadowed the era of targeted therapy, thereby helping clinicians interpret early biomarker-driven strategies and their implications for personalized treatment.

In more recent years, ONCOLOGY has captured some of the most consequential advances in contemporary cancer care, including the emergence of immune checkpoint inhibition, cellular therapies, and novel immuno-oncology combinations. Alongside reports of efficacy, the journal has emphasized thoughtful discussion of toxicity, sequencing, patient selection, and durability of benefit. This approach recognizes that the impact of innovation depends on how it is applied in real-world practice.

Importantly, ONCOLOGY has consistently looked beyond tumor response alone. Over the past 4 decades, its pages have increasingly reflected the field’s expanding priorities: survivorship, symptom management, quality of life, and the long-term consequences of therapy. As oncology treatment has progressed, so too has the journal’s commitment to addressing the full spectrum of patient experience.

Throughout this period of extraordinary change, ONCOLOGY, housed within CancerNetwork, has evolved alongside the field by adapting its scope, formats, and perspectives while remaining grounded in its core mission: to disseminate high-quality data and provide clinically meaningful interpretation for practicing oncologists and cancer researchers.

This legacy is the result of a collective effort. We are deeply grateful to the investigators who shared their discoveries, the reviewers who ensured rigor and balance, and the editorial leaders and staff who stewarded the journal through decades of progress. Above all, we thank our contributors and readers, whose engagement and trust continue to guide the journal’s direction.

Today, oncology stands at another inflection point. Advances in genomics, immunology, prevention, digital health, and implementation science offer unprecedented opportunity, even as challenges related to equity, access, cost, and survivorship demand renewed focus. In this environment, the role of a clinically grounded journal that helps contextualize discovery and translate evidence into care is more essential than ever.

As ONCOLOGY enters its fifth decade, we remain committed to the principles that have defined the journal since its inception: scientific excellence, clinical relevance, and an unwavering focus on improving the experience and outcomes for people living with cancer. This special anniversary issue honors the progress of the past 40 years while reaffirming our responsibility to help shape the future of cancer research and care.

Thank you for being part of this journey.